Protection against development of otitis media induced by nontypeable Haemophilus influenzae by both active and passive immunization in a chinchilla model of virus-bacterium superinfection.
Three separate studies, two involving active-immunization regimens and one involving a passive-transfer protocol, were conducted to initially screen and ultimately more fully assess several nontypeable Haemophilus influenzae outer membrane proteins or their derivatives for their relative protective efficacy in chinchilla models of otitis media. Initial screening of these antigens (P5-fimbrin, lipoprotein D, and P6), delivered singly or in combination with either Freund's adjuvant or alum, indicated that augmented bacterial clearance from the nasopharynx, the middle ears, or both anatomical sites could be induced by parenteral immunization with P5-fimbrin combined with lipoprotein D, lipoprotein D alone, or the synthetic chimeric peptide LB1 (derived from P5-fimbrin), respectively. Data from a second study, wherein chinchillas were immunized with LB1 or lipoprotein D, each delivered with alum, again indicated that clearance of nontypeable H. influenzae could be augmented by immunization with either of these immunogens; however, when this adjuvant was used, both antibody titers in serum and efficacy were reduced. A third study was performed to investigate passive delivery of antisera directed against either LB1, lipoprotein D, nonacylated lipoprotein D, or a unique recombinant peptide designated LPD-LB1(f)2,1,3. The last three antiserum pools were generated by using the combined adjuvant of alum plus monophosphoryl lipid A. Passive transfer of sera specific for LB1 or LPD-LB1(f)2,1,3 to adenovirus-compromised chinchillas, prior to intranasal challenge with nontypeable H. influenzae, significantly reduced the severity of signs and incidence of otitis media which developed (P </= 0.001). Collectively, these data indicate the continued merit of further developing LB1 and LPD-LB1(f)2,1,3 as components of vaccines for otitis media.
Bakaletz
L O
LO
Division of Otologic Research, Department of Otolaryngology, College of Medicine, The Ohio State University, Columbus, Ohio, USA. BakaletL@pediatrics.ohio-state.edu
Kennedy
B J
BJ
Novotny
L A
LA
Duquesne
G
G
Cohen
J
J
Lobet
Y
Y
D000595:Amino Acid Sequence; D000818:Animals; D001053:Apolipoproteins / Q000276:immunology; D053399:Apolipoproteins D; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology; D002682:Chinchilla; D004195:Disease Models, Animal; D005784:Gene Amplification; D006192:Haemophilus Infections / Q000517:prevention & control*; D018073:Haemophilus Vaccines / Q000276:immunology*; D006193:Haemophilus influenzae / Q000276:immunology*; D007116:Immunization, Passive / Q000379:methods; D007150:Immunohistochemistry; D008969:Molecular Sequence Data; D010033:Otitis Media / Q000517:prevention & control*; D010034:Otitis Media with Effusion; D016133:Polymerase Chain Reaction; D015163:Superinfection / Q000517:prevention & control*; D014432:Tympanic Membrane; D014611:Vaccination / Q000379:methods; D014614:Vaccines, Synthetic / Q000276:immunology; D014777:Virus Diseases / Q000517:prevention & control
D001053:Apolipoproteins; D053399:Apolipoproteins D; D001425:Bacterial Outer Membrane Proteins; D018073:Haemophilus Vaccines; C069990:P6 outer membrane protein, Haemophilus; D014614:Vaccines, Synthetic; C082912:outer membrane protein P5, Haemophilus